Skip to main content
. 2020 Apr 16;31(7):693–701. doi: 10.1097/CAD.0000000000000934

Fig. 1.

Fig. 1

DEX inhibits the proliferation and metastasis while promotes the apoptosis of esophageal cancer cells. (a and b) The proliferation of esophageal cancer cells treated with control, negative control or DEX was determined by MTT assay. (c) Flow cytometry was carried out to measure the apoptosis of esophageal cancer cells treated with control, negative control or DEX. (d and e) The invasion and migration of KYSE150 and ECA-109 cells treated with control, negative control or DEX were determined by transwell migration and invasion assays. (f and g) Western blot assay was applied to detect the abundance of proliferation-associated protein (Cyclin D1), apoptosis-related proteins (Bcl-2 and Bax) and metastasis-associated proteins (Vimentin and E-cadherin) in KYSE150 and ECA-109 cells treated with control, negative control or DEX. *P < 0.05. DEX, dexmedetomidine; MTT assay, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.